secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088051
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q2 net loss $20.4M; DKN-01 ORR 33% in CRC; $40M PIPE completed
--------------------------------------------------------------------------------

- Net loss of $20.4M in Q2 2024 vs $13.4M in Q2 2023; R&D expenses rose to $17.9M on trial costs.
- DKN-01 combo achieved 33% ORR (38% left-sided) in Part A of DeFianCe CRC study; median PFS 6.3 months.
- Enrollment in Part B expanded to 180 patients; completion expected Sept 2024, data mid-2025.
- DisTinGuish Part C gastric/GEJ cancer data expected Q4 2024 or early 2025.
- Completed $40M private placement with Gilead, Samsara, others; cash $78.5M funds into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924088051/0001104659-24-088051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924088051/tm2421304d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer